NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NVCR NovoCure

Market Closed 10-30 16:00:00 EDT

13.15

+0.04

+0.31%

盘后13.15

+0.000.00%

19:30 EDT

High13.26	Low12.52	Vol1.97M
Open12.81	D1 Closing13.11	Amplitude5.68%
Mkt Cap1.53B	Tradable Cap1.27B	Total Shares116.45M
T/O25.68M	T/O Rate2.05%	Tradable Shares96.42M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NVCR","market":"US","secType":"STK","nameCN":"NovoCure","latestPrice":13.15,"timestamp":1793390400000,"preClose":13.11,"halted":0,"volume":1974509,"hourTrading":{"tag":"盘后","latestPrice":13.15,"preClose":13.15,"latestTime":"19:30 EDT","volume":9191,"amount":120863.85,"timestamp":1793403002773,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.0030511060259344716,"floatShares":96423600,"shares":116445840,"eps":-1.308249,"marketStatus":"Market Closed","change":0.04,"latestTime":"10-30 16:00:00 EDT","open":12.81,"high":13.26,"low":12.515,"amount":25677186.36906,"amplitude":0.056827,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.308249,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1793610000000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1443758400000,"exchange":"NASDAQ","adjPreClose":13.11,"preHourTrading":{"tag":"盘前","latestPrice":12.81,"preClose":13.11,"latestTime":"09:29 EDT","volume":462,"amount":5935.621692,"timestamp":1793366999999,"change":-0.3,"changeRate":-0.022883,"amplitude":0.022883},"postHourTrading":{"tag":"盘后","latestPrice":13.15,"preClose":13.15,"latestTime":"19:30 EDT","volume":9191,"amount":120863.85,"timestamp":1793403002773,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.7537327830936844,"impliedVol":0.5188,"impliedVolPercentile":0.1275},"requestUrl":"/m/hq/s/NVCR","defaultTab":"news","newsList":[{"id":"2679214912","title":"Novocure Price Target Cut to $20.00/Share from $23.00 by Evercore ISI Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2679214912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679214912?lang=en_us&edition=fundamental","pubTime":"2026-10-30 20:51","pubTimestamp":1793364660,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NVCR/analyst-ratings","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4548","BK4082","BK4534","BK4588","NVCR","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679121571","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: NovoCure (NVCR), PTC Therapeutics (PTCT) and Encompass Health (EHC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2679121571","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679121571?lang=en_us&edition=fundamental","pubTime":"2026-10-30 19:40","pubTimestamp":1793360453,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on NovoCure (NVCR), PTC Therapeutics (PTCT) and Encompass Health (EH...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-novocure-nvcr-ptc-therapeutics-ptct-and-encompass-health-ehc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-novocure-nvcr-ptc-therapeutics-ptct-and-encompass-health-ehc-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["EHC","LU0054578231.USD","EH","XBI","HCSG","LABU","BK4187","LU0320765992.SGD","SG9999004303.SGD","BK4082","BK4603","LU2237957902.USD","LU0889565916.HKD","BK4588","LU1983260115.SGD","BK4185","XLV","BK4139","BK4548","BK4585","LU0128526141.USD","PTCT","NVCR","BK4137","SGXZ23171101.USD","BK4581","LU0029874061.USD","LU2237957811.SGD","BK4534","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679255980","title":"Novocure Raises 2026 Outlook as Q3 Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2679255980","media":"TradingKey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679255980?lang=en_us&edition=fundamental","pubTime":"2026-10-30 08:06","pubTimestamp":1793318806,"startTime":"0","endTime":"0","summary":"Novocure raised its 2026 revenue and adjusted EBITDA forecasts after Q3 revenue climbed 15.7%, losses narrowed and Optune Pax gained early uptake.","market":"fut","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock10.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/presentation/262257337-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","NVCR","BK4585","BK4082","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679234662","title":"NovoCure Limited Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2679234662","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679234662?lang=en_us&edition=fundamental","pubTime":"2026-10-30 05:01","pubTimestamp":1793307669,"startTime":"0","endTime":"0","summary":"NovoCure Limited reports results for the quarter ended September 30 - Earnings SummaryNovoCure LimitedNVCR.OQreported a quarterly adjusted loss of 9 cents per share for the quarter ended September 30,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nL5N46F3Q0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4534","NVCR","BK4588","BK4548","BK4082","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679466284","title":"Novocure’s Pax disrupted by Revolution rollout, says Wedbush","url":"https://stock-news.laohu8.com/highlight/detail?id=2679466284","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679466284?lang=en_us&edition=fundamental","pubTime":"2026-10-29 23:55","pubTimestamp":1793289319,"startTime":"0","endTime":"0","summary":"Wedbush notes that active patients on Novocure’s (NVCR) Optune Pax declined to 276 in Q3 from 285 in Q2, reporting that management cited disruption...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/novocures-pax-disrupted-by-revolution-rollout-says-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/novocures-pax-disrupted-by-revolution-rollout-says-wedbush-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4534","BK4082","BK4585","BK4588","BK4548","NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679860942","title":"NovoCure Shares Fall After Narrower Q3 Loss, Revenue Beat","url":"https://stock-news.laohu8.com/highlight/detail?id=2679860942","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679860942?lang=en_us&edition=fundamental","pubTime":"2026-10-29 22:22","pubTimestamp":1793283734,"startTime":"0","endTime":"0","summary":"NovoCure  shares fell 9.6% in early Thursday trading after the company reported a narrower Q3 loss and revenue that beat expectations.The company reported a Q3 net loss Thursday of $0.09 per diluted share, narrowing from a loss of $0.33 a year earlier.Analysts polled by FactSet expected a loss of $0.23.Revenue for the quarter ended Sept. 30 was $193.4 million, up from $167.2 million a year earlier.Analysts expected $182.3 million.The company raised its 2026 revenue guidance to $736 million to $743 million from the prior guidance of $710 million to $725 million. Analysts expect $726.1 million.Price: 12.81, Change: -1.36, Percent Change: -9.60","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679405403","title":"GUIDANCE: (NVCR) NovoCure Expects 2026 Revenue Range $736M - $743M, vs. FactSet Est of $726.1M","url":"https://stock-news.laohu8.com/highlight/detail?id=2679405403","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679405403?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:22","pubTimestamp":1793272929,"startTime":"0","endTime":"0","summary":"GUIDANCE: (NVCR) NovoCure Expects 2026 Revenue Range $736M - $743M, vs. FactSet Est of $726.1M","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679740551","title":"Switzerland's Novocure Q3 Revenue Rises 16%, Beats Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2679740551","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679740551?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:18","pubTimestamp":1793272723,"startTime":"0","endTime":"0","summary":"Switzerland's Novocure Q3 revenue rises 16%, beats estimatesOverviewGlobal oncology company's Q3 revenue rose 16% yr/yr, beating analyst expectationsCompany raised full-year 2026 revenue and adjusted ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nL2N46F0LB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541273.HKD","LU2491050154.USD","LU2362540622.SGD","IE0009354923.USD","LU0432979614.USD","SG9999001176.USD","IE0002141913.USD","BK4588","IE00BFTCPJ56.SGD","IE00B2B36J28.USD","LU2491049909.HKD","LU2087625088.SGD","SG9999013999.USD","LU1791710400.SGD","LU1720051108.HKD","LU1791710582.SGD","LU0138981039.USD","LU1989764748.USD","LU1989772923.USD","BK4504","LU0122379950.USD","LU0187121727.USD","LU0882574055.USD","LU0267386448.USD","LU2506951875.HKD","LU0011850046.USD","LU1989764664.SGD","LU1720051017.SGD","LU1023059063.AUD","LU0225283273.USD","NVCR","LU1057294990.SGD","LU0823417737.USD","LU2491050071.SGD","LU1061106388.HKD","LU2244417387.USD","LU0077335932.USD","LU2357305700.SGD","LU2265009873.SGD","GKOS","LU2506952170.USD","BSX","LU2242649171.HKD","LU0266013472.USD","LU1153585028.USD","BK4581","LU2065731478.USD","LU1878469433.USD","BK4548","LU0950375773.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679403217","title":"Earnings Flash (NVCR) NovoCure Posts Q3 Loss $0.09 a Share, vs. FactSet Est of $0.23 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2679403217","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679403217?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:11","pubTimestamp":1793272279,"startTime":"0","endTime":"0","summary":"Earnings Flash (NVCR) NovoCure Posts Q3 Loss $0.09 a Share, vs. FactSet Est of $0.23 Loss","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679403658","title":"Novocure Q3 Net Loss Narrows 72% to USD 10.44 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2679403658","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679403658?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:06","pubTimestamp":1793272006,"startTime":"0","endTime":"0","summary":"Novocure Q3 net loss narrows 72% to USD 10.44 millionNovocure’s third-quarter 2026 net loss narrowed 72% year over year to $10.44 million.Net revenues rose 16% year over year to $193.4 million, driven","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nNDL5tXNWd:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4548","BK4585","BK4588","NVCR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679087974","title":"NovoCure Q3 EPS $(0.09) Beats $(0.24) Estimate, Sales $193.399M Beat $182.233M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2679087974","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679087974?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:01","pubTimestamp":1793271705,"startTime":"0","endTime":"0","summary":"NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.24) by 62.5 percent. This is a 72.73 percent increase over losses of $(0.33) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/10/62688189/novocure-q3-eps-0-09-beats-0-24-estimate-sales-193-399m-beat-182-233m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NVCR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679408210","title":"Novocure Q3 Revenue USD 193.399 Million Vs. IBES Estimate USD 182.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2679408210","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679408210?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:01","pubTimestamp":1793271664,"startTime":"0","endTime":"0","summary":"BRIEF-Novocure Q3 Revenue USD 193.399 Million Vs. IBES Estimate USD 182.2 MillionOct 29 (Reuters) - Novocure Q3 pretax profit USD -7.88 million.Q3 operating income USD -6.171 millionQ3 net income USD -10.435 millionQ3 gross profit USD 148.87 million","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nPLXR1Z03T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NVCR","BK4534","BK4082","BK4548","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679640559","title":"Novocure - U.S. FDA Decision Expected Q4 2026 on Ttfields for Brain Metastases from Nsclc","url":"https://stock-news.laohu8.com/highlight/detail?id=2679640559","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679640559?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:00","pubTimestamp":1793271604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nPLXR1Z03T:6","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4548","BK4534","BK4082","NVCR","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679408520","title":"Novocure Q3 Gross Profit USD 148.87 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2679408520","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679408520?lang=en_us&edition=fundamental","pubTime":"2026-10-29 19:00","pubTimestamp":1793271604,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261029:nPLXR1Z03T:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4082","BK4548","BK4585","BK4588","NVCR","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678469263","title":"Novocure Partners with Verastem Oncology on Pancreatic Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2678469263","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678469263?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:02","pubTimestamp":1793185347,"startTime":"0","endTime":"0","summary":"Novocure Partners With Verastem Oncology on Pancreatic Cancer TrialNovocure entered a clinical trial collaboration and supply agreement with Verastem Oncology to evaluate a combination treatment for l","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nNDL6Knnm3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VSTM","BK4082","BK4139","BK4585","NVCR","BK4534","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678718466","title":"Novocure to Evaluate Tumor Treating Fields Therapy with Vs-7375, an Oral Kras G12d (on/off) Inhibitor, to Treat Pancreatic Cancer Through Clinical Trial Collaboration and Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2678718466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678718466?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUACFWDYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NVCR","BK4585","BK4082","BK4588","BK4534","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678667464","title":"Novocure - Enters Clinical Trial Collaboration and Supply Agreement with Verastem Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2678667464","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678667464?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUACFWDYN:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4534","NVCR","BK4548","BK4585","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678660334","title":"Novocure - Trial Expected to Begin Enrolling Patients in 2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2678660334","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678660334?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUACFWDYN:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4139","NVCR","BK4585","BK4082","VSTM","BK4588","BK4548"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678646605","title":"Novocure - to Manage and Fund Trial; Verastem to Supply Vs-7375","url":"https://stock-news.laohu8.com/highlight/detail?id=2678646605","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678646605?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUACFWDYN:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4588","BK4548","BK4585","BK4139","BK4534","NVCR","VSTM","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678466703","title":"Novocure - to Evaluate Ttfields Therapy with Chemotherapy and Vs-7375 for Pancreatic Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2678466703","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678466703?lang=en_us&edition=fundamental","pubTime":"2026-10-28 19:00","pubTimestamp":1793185202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nTUACFWDYN:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4534","BK4082","BK4585","BK4588","BK4548","NVCR"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.novocure.com","stockEarnings":[{"period":"1week","weight":-0.1042},{"period":"1month","weight":-0.1755},{"period":"3month","weight":-0.1139},{"period":"6month","weight":-0.2088},{"period":"1year","weight":0.0257},{"period":"ytd","weight":0.017}],"compareEarnings":[{"period":"1week","weight":-0.0056},{"period":"1month","weight":-0.0091},{"period":"3month","weight":0.0116},{"period":"6month","weight":0.0487},{"period":"1year","weight":0.1116},{"period":"ytd","weight":0.1082}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optune Lua for the treatment of malignant pleural mesothelioma. The company also has ongoing or completed clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. The company was incorporated in 2000 and is headquartered in Saint Helier, Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.272727,"avgChangeRate":-0.026321},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.001726},{"month":3,"riseRate":0.454545,"avgChangeRate":-0.034505},{"month":4,"riseRate":0.545455,"avgChangeRate":0.108267},{"month":5,"riseRate":0.818182,"avgChangeRate":0.133305},{"month":6,"riseRate":0.363636,"avgChangeRate":-0.03448},{"month":7,"riseRate":0.454545,"avgChangeRate":-0.006046},{"month":8,"riseRate":0.636364,"avgChangeRate":0.035375},{"month":9,"riseRate":0.363636,"avgChangeRate":-0.028188},{"month":10,"riseRate":0.181818,"avgChangeRate":-0.099312},{"month":11,"riseRate":0.636364,"avgChangeRate":0.077306},{"month":12,"riseRate":0.545455,"avgChangeRate":0.065178}],"exchange":"NASDAQ","name":"NovoCure","nameEN":"NovoCure"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"NovoCure,NVCR,NovoCure股票,NovoCure股票老虎,NovoCure股票老虎国际,NovoCure行情,NovoCure股票行情,NovoCure股价,NovoCure股市,NovoCure股票价格,NovoCure股票交易,NovoCure股票购买,NovoCure股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"NovoCure(NVCR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest NovoCure(NVCR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}